

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-Dec-2016  
Document Type: USP Monographs  
DocId: GUID-1BB8F063-884A-4921-A25F-0AD404914611\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M1801\\_01\\_01](https://doi.org/10.31003/USPNF_M1801_01_01)  
DOI Ref: pjx2v

© 2025 USPC  
Do not distribute

# Tramadol Hydrochloride Compounded Oral Suspension

**DEFINITION**  
Tramadol Hydrochloride Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of tramadol hydrochloride ( $C_{16}H_{25}NO_2 \cdot HCl$ ).

Prepare Tramadol Hydrochloride Compounded Oral Suspension 5 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Tramadol Hydrochloride tablets <sup>a</sup> equivalent to	500 mg of tramadol hydrochloride
Vehicle: a 1:1 mixture of Ora-Sweet <sup>b</sup> (sugar-free) and Ora-Plus, <sup>b</sup> a sufficient quantity to make	100 mL

- <sup>a</sup> Ultram 50-mg tablets, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ.  
<sup>b</sup> Paddock Laboratories, Minneapolis, MN.

Calculate the required quantity of each ingredient for the total amount to be prepared. Place the required number of *Tramadol Hydrochloride tablets* in a suitable mortar, and comminute to a fine powder. Add the *Vehicle* in small portions, and triturate to make a smooth paste. Add increasing volumes of the *Vehicle* to make a tramadol hydrochloride liquid that is pourable. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add enough of the *Vehicle* to bring to final volume, and mix well.

**ASSAY**

• **PROCEDURE**

**Solution A:** 20 mM of phosphoric acid and 4 g/L of sodium 1-hexane sulfonate  
**Mobile phase:** Acetonitrile and *Solution A* (50:50). Filter and degas.  
**Diluent:** Acetonitrile and water (50:50)  
**Standard solution:** 0.25 mg/mL of [USP Tramadol Hydrochloride RS](#) in *Diluent*  
**Sample solution:** Shake thoroughly by hand each bottle of Oral Suspension. Prepare 0.25 mg/mL of tramadol hydrochloride from Oral Suspension and *Diluent*, and centrifuge.

**Chromatographic system**  
(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC  
**Detector:** UV 275 nm  
**Column:** 4.6-mm × 25-cm; 5-μm packing L1  
**Column temperature:** 30°  
**Flow rate:** 1.0 mL/min  
**Injection volume:** 5 μL

**System suitability**

**Sample:** *Standard solution*  
[NOTE—The retention time for tramadol hydrochloride is about 6 min.]  
**Suitability requirements**

**Relative standard deviation:** NMT 2.0% for replicate injections

**Analysis**

**Samples:** *Standard solution* and *Sample solution*  
Calculate the percentage of the labeled amount of tramadol hydrochloride ( $C_{16}H_{25}NO_2 \cdot HCl$ ) in the portion of Oral Suspension taken:

Result =  $(r_U/r_S) \times (C_S/C_U) \times 100$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Tramadol Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of tramadol hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

#### SPECIFIC TESTS

- **pH** (791): 3.8–4.8

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator or at controlled room temperature.
- **BEYOND-USE DATE:** NMT 90 days after the date on which it was compounded when stored in a refrigerator or controlled room temperature
- **LABELING:** Label it to indicate that it is to be well shaken before use, and to state the *Beyond-Use Date*.
- **USP REFERENCE STANDARDS** (11).  
[USP Tramadol Hydrochloride RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TRAMADOL HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION	<a href="#">Brian Serumaga</a> Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	CMP2020 Compounding 2020

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(1)

**Current DocID:** GUID-1BB8F063-884A-4921-A25F-0AD404914611\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M1801\\_01\\_01](https://doi.org/10.31003/USPNF_M1801_01_01)

**DOI ref:** [pjx2v](#)